Campath 1H

Phase 2Small molecule

Mario Negri Institute for Pharmacological Research

Campath 1H is one of 471 small molecule programs targeting Macroglobulinemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

470

Competitors

Pipeline

Status by Indication[3][1]

Indication

MacroglobulinemiaActive, not recruiting

VasculitisActive, not recruiting

Tic DisorderActive, not recruiting

LymphomaActive, not recruiting

LeukemiaActive, not recruiting

Kidney TransplantActive, not recruiting

Dyskeratosis CongenitaActive, not recruiting

Hematologic DiseaseActive, not recruiting

Bone Marrow TransplantationActive, not recruiting

ImmunodeficiencyActive, not recruiting

MacroglobulinemiaPhase 2

Active, not recruiting

VasculitisPhase 1

Active, not recruiting

Tic DisorderPhase 2

Active, not recruiting

LymphomaPhase 2

Active, not recruiting

LeukemiaPhase 1

Active, not recruiting

Kidney TransplantPhase 2

Active, not recruiting

Dyskeratosis CongenitaPhase 2/Phase 3

Active, not recruiting

Hematologic DiseasePhase 1/Phase 2

Active, not recruiting

Bone Marrow TransplantationPreclinical

Active, not recruiting

ImmunodeficiencyPhase 1/Phase 2

Active, not recruiting

Showing 10 of 18 indications

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Campath 1H

Mario Negri Institute for Pharmacological Research

Phase 2

1 2

Oncaspar

SServier

Preclinical

15 3

Zofran

Novartis

Preclinical

2 4

Norvir

AbbVie

Preclinical

1 5

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 6

Tafasitamab

Incyte

Preclinical

7 7

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 8

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 9

Nuvigil

NNuvo Research GmbH

Preclinical

1 10

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Stem Cell Transplantation3 trials

Donor Stem Cell Transplantation for Congenital Immunodeficiencies

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00426517·48 enrolled

Stem Cell Transplantation for Patients With Graft Failure Following an Allogeneic Transplant, Using Identical or Near Identical Donors and Less Toxic Conditioning With CAMPATH 1H

Terminated·—·Phase 1/2·NCT00048399·40 enrolled

Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies

Terminated·MM.D. Anderson Cancer Center·N/A·NCT00038883·19 enrolled

Renal Transplantation3 trials

Campath-1H Induction to Allow Steroid Free Immunosuppression in Pediatric Renal Transplantation

Terminated·UUniversity of Wisconsin, Madison·Phase 1/2·NCT00167661·33 enrolled

Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Living Donor Renal Transplantation

Completed·UUniversity of Miami·Phase 4·NCT00681343·38 enrolled

Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Deceased Donor Renal Transplantation

Completed·UUniversity of Miami·Phase 4·NCT00685061·90 enrolled

Hematopoietic Stem Cell Transplantation2 trials

Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00668564·18 enrolled

Feasibility of Haploidentical Hematopoietic Stem Cell Transplantation Using CAMPATH-1H

Completed·TTehran University of Medical Sciences·Phase 1·NCT00458250·10 enrolled

Fanconi Anemia2 trials

Use of Rft5-Dga to Deplete Alloreactive Cells for Pts With Fanconi Anemia After Haploidentical SCT

Terminated·—·Phase 1·NCT00586274·1 enrolled

Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia

Terminated·—·Phase 1/2·NCT00590460·5 enrolled

Stem Cell Transplant2 trials

Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H

Completed·—·Phase 1/2·NCT00048412·40 enrolled

T-Reg Cell Kinetics, Stem Cell Transplant, REGALE

Terminated·—·N/A·NCT00578539·24 enrolled

26 more indications

Dyskeratosis Congenita1 trial

Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2/3·NCT00455312·36 enrolled

Chronic Lymphocytic Leukemia1 trial

Continuous Infusion of Campath-1H Followed by Subcutaneous Injections in Previously Treated Patients With Chronic Lymphocytic Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00102661·10 enrolled

Leukemia1 trial

Anti-Human CD45 Monoclonal Antibodies in Patients With Advanced Leukemia Prior to Allogeneic Stem Cell Transplantation

Completed·—·Phase 1·NCT00057005·6 enrolled

Bone Marrow Transplantation1 trial

Bone Marrow Transplantation, Hemoglobinopathies, SCALLOP

Terminated·TTami D. John·N/A·NCT00578344·8 enrolled

Macroglobulinemia1 trial

Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia

Completed·—·Phase 2·NCT00142181·27 enrolled

Severe Aplastic Anemia1 trial

Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00065260·54 enrolled

Allogeneic Hematopoietic Stem Cell Transplantation1 trial

Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases

Completed·—·Phase 1/2·NCT00056966·24 enrolled

Transplantation1 trial

"A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52) Therapy in Primary Renal Allograft Transplantation"

Completed·UUniversity of Wisconsin, Madison·Phase 2·NCT00365846·29 enrolled

Immunodeficiency1 trial

Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders

Terminated·—·Phase 1/2·NCT00579137·3 enrolled

Thalassemia1 trial

Allogeneic Stem Cell Transplantation, Severe Homzygous 0/+Thalassemia or Sever Variants of Beta 0/+ Thalassemia, THALLO

Terminated·—·N/A·NCT00578292·10 enrolled

Lymphoma1 trial

Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00505921·27 enrolled

Stem Cell1 trial

T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts

Completed·—·Phase 2·NCT00368355·46 enrolled

Osteopetrosis1 trial

Allogeneic Transplantation For Severe Osteopetrosis

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2/3·NCT00775931·7 enrolled

Allogeneic Stem Cell Transplantation1 trial

Monoclonal Antibody Conditioning for Allogeneic Stem Cell Transplantation of Patients With Inherited Metabolic Storage Diseases

Terminated·—·Phase 1/2·NCT00056979·2 enrolled

Myeloproliferative Disorder1 trial

Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML

Terminated·—·Phase 2·NCT00069992·7 enrolled

Lymphoid Malignancies1 trial

Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00536978·22 enrolled

Kidney Transplant1 trial

Low Dose Sirolimus or CsA-Based Maintenance Immunosuppression After Induction With Campath-1 in Kidney Transplantation

Completed· Mario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research·Phase 2·NCT00309270·21 enrolled

Hematopoietic Stem Cell Transplant1 trial

Reduced-Intensity Hematopoietic Stem Cell Transplant for High Risk Lysosomal and Peroxisomal Disorders

Completed·MMasonic Cancer Center, University of Minnesota·N/A·NCT01626092·3 enrolled

Vasculitis1 trial

Hematopoietic Stem Cell Support in Vasculitis

Terminated·NNorthwestern University·Phase 1·NCT00278512·7 enrolled

Hematologic Disease1 trial

Stem Cell Transplant for Hematologic Diseases

Terminated·—·Phase 1/2·NCT00058825·27 enrolled

Tic Disorder1 trial

Stem Cell Transplant for Immunologic or Histiocytic Disorders

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00176865·19 enrolled

Refractory1 trial

Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00071396·48 enrolled

Bone Marrow Transplant1 trial

Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies

Terminated·—·Phase 2·NCT00040469·15 enrolled

Inherited Metabolic Disorders1 trial

Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT01043640·46 enrolled

Rheumatoid Arthritis1 trial

Rheumatoid Arthritis:Tolerance Induction by Mixed Chimerism

Terminated·NNorthwestern University·Phase 1·NCT00282412·4 enrolled

Type 1 Diabetes Mellitus1 trial

A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52 Antibody) Therapy in Newly Diagnosed Subjects With Type 1 Diabetes Mellitus

Withdrawn·UUniversity of Wisconsin, Madison·Phase 1·NCT00214214

Sources

References

[1]
ClinicalTrials.gov — 38 trial records for Campath 1H. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Campath 1H compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Campath 1H. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mario Negri Institute for Pharmacological Research company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Mario Negri Institute for Pharmacological Research

Campath 1H

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Stem Cell Transplantation3 trials

Renal Transplantation3 trials

Hematopoietic Stem Cell Transplantation2 trials

Fanconi Anemia2 trials

Stem Cell Transplant2 trials

Dyskeratosis Congenita1 trial

Chronic Lymphocytic Leukemia1 trial

Leukemia1 trial

Bone Marrow Transplantation1 trial

Macroglobulinemia1 trial

Severe Aplastic Anemia1 trial

Allogeneic Hematopoietic Stem Cell Transplantation1 trial

Transplantation1 trial

Immunodeficiency1 trial

Thalassemia1 trial

Lymphoma1 trial

Stem Cell1 trial

Osteopetrosis1 trial

Allogeneic Stem Cell Transplantation1 trial

Myeloproliferative Disorder1 trial

Lymphoid Malignancies1 trial

Kidney Transplant1 trial

Hematopoietic Stem Cell Transplant1 trial

Vasculitis1 trial

Hematologic Disease1 trial

Tic Disorder1 trial

Refractory1 trial

Bone Marrow Transplant1 trial

Inherited Metabolic Disorders1 trial

Rheumatoid Arthritis1 trial

Type 1 Diabetes Mellitus1 trial

References

Drug Info

Quick Facts

Related News